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Novel Angiographic Scores for 
evaluation of Large Vessel Vasculitis
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Arterial involvement is the cardinal feature of large-vessel vasculitis (LVV) and prevention of disease 
progression is the principal therapeutic goal. However, development of tools for its evaluation 
represents a major unmet need. To address this, a widely-applicable imaging tool for LVV, analysing 
arterial involvement in 17 arterial territories, has been developed and validated. Individual stenosis and 
dilation scores were generated and combined in a composite score. The methodology was validated 
cross-sectionally and longitudinally in 131 patients, 96 Takayasu arteritis (TA), 35 large-vessel giant-
cell arteritis (LV-GCA). In total, 4420 arterial segments from 260 imaging studies were evaluated. The 
new scores allowed quantitative grading of LVV arterial involvement with high consistency, revealing 
inter-patient differences. TA had higher stenosis and composite scores and lower dilation scores than 
LV-GCA. Baseline stenotic and composite scores reflected arterial damage rather than disease-activity. 
Longitudinal changes in all three scores correlated with disease activity and mirrored arterial disease 
evolution, reflecting both progressive injury and lesion improvement. Increases ≥1 in any score were 
specific for arterial disease progression. The scores objectively quantify arterial involvement in LVV, 
providing precise definition of disease phenotype and evolution. We propose that they represent novel 
vascular outcome measures essential for future clinical trials.
Large-vessel vasculitides (LVVs) are characterised by idiopathic arterial inflammation predisposing to vascular 
remodelling with stenosis/occlusion or dilation1–3. The two predominant LVVs are Takayasu arteritis (TA) and 
giant-cell arteritis (GCA), typically affecting young and elderly patients, respectively2. When compared to the 
progress made in recent decades in other inflammatory rheumatic diseases, clinical advances in LVV have been 
incremental and management remains sub-optimal4. Although biologic therapies for GCA5 and TA6,7 are begin-
ning to change the perspective, their use raises important issues. These include the limitations associated with 
current disease activity assessments based on clinical symptoms or acute-phase reactants (C-reactive protein 
(CRP) and erythrocyte-sedimentation rate (ESR))8–12 and in the multi-item measures including the National 
Institute of Health (NIH) criteria and Indian Takayasu Activity Score (ITAS)11,13. Symptom suppression does 
not necessarily reflect remission of arterial wall inflammation and silent arterial disease progression has been 
reported, especially during tocilizumab therapy9,14,15. Thus, imaging is required for diagnosis and serially every 
6–12 months to monitor arterial remodeling in those with persistently active or grumbling disease. However, 
imaging is not routinely recommended for patients in clinical and biochemical remission with stable imaging 
studies12,16,17.
Arterial injury directly impacts LVV clinical features and prognosis4. Prevention of arterial disease progres-
sion is the fundamental therapeutic goal12. However, evidence demonstrating the effects of immunosuppressive 
therapy remains relatively sparse. Clinical trial outcomes have predominantly reflected changes in disease activity, 
with the imaging assessment of arterial disease incorporated as a secondary end-point5–7. This omission reflects 
the lack of standardised and validated non-invasive imaging outcome measures18. The recent report from the 
OMERACT group stresses the urgent need for defined outcome measures for LVV19. Likewise, the 2018 EULAR 
LVV Imaging Guidelines specifically recommend the development of ‘standardised, well-validated scoring 
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methodologies for all imaging modalities’ and ‘composite scores for imaging-based monitoring of patients with 
LVV’17.
These well-recognised challenges formed the basis of the current study. A novel imaging-based scoring algo-
rithm has been designed to allow precise qualitative and quantitative definition of arterial involvement in LVV 
based on luminal changes. Additional goals were wide applicability and utility for both cross-sectional and longi-
tudinal disease assessment in future clinical trials. To achieve this, validated methods for assessing carotid artery 
atherosclerosis were modified to account for specific LVV features. Three new scores were generated: a Stenosis 
and a Dilation Score, which were combined in a Composite Score. The three scores were then tested in a large 
LVV cohort to provide cross-sectional and longitudinal validation.
Results
Development of arterial injury scores. The novel LVV scores were designed to be applicable to volumet-
ric computed tomography-angiography (CTA) and magnetic resonance-angiography (MRA) studies. The scor-
ing algorithm was derived from the well-validated North American Symptomatic Carotid Endarterectomy Trial 
(NASCET) and European Carotid Surgery Trial (ECST) methods. These scores utilise luminal data to define the 
severity of carotid atherosclerosis on the basis of percent stenosis20,21, but differ in the reference used to calculate 
percent stenosis (Supplementary Fig. 1). The detail behind the modification of NASCET and ECST for the assess-
ment of LVV is included in the Methods section of the manuscript and is illustrated in Fig. 1. The modifications 
allowed assessment of a core-set of 17 arteries, selected on the basis of: (a) frequent involvement in LVV10,22 and 
(b) suitability for analysis by routine contrast-enhanced MRA and CTA (Table 1).
Application of the scoring algorithm. The novel scoring algorithm was initially applied to the imag-
ing studies of 131 consecutive LVV patients fulfilling enrolment criteria (96 TA, 35 LV-GCA), followed for 3.1 
years (IQR 1.4–4.9). Two physicians jointly evaluated 260 scans and 4420 arterial segments, requiring on average 
30–40 minutes per scan. Supplementary Table 1 shows descriptive statistics at baseline. Compared to LV-GCA, TA 
patients had longer disease duration, more extensive arterial damage and fewer were receiving corticosteroids. The 
stenotic, dilation and composite scores were generated in all cases. Illustrative examples are shown in Figs 2 and 3. 
A specific, independent subset analysis demonstrated a high level of scoring consistency (intra- and inter-observer 
reliability of the stenosis, dilation and composite scores of 0.999–0.996-0.996 and 0.995–0.993–0.992, 
respectively). Baseline scans (114 MRAs, 17 CTAs) showed a wide range of stenotic, dilation and composite 
scores (0–50, 0–26 and 0–53, respectively). These data demonstrate the full range of disease severity present in 
the cohort. Furthermore, they suggest that the scores have the potential to stratify individual patients based on 
the extent of arterial stenosis and dilation.
The novel scores reflect disease phenotype heterogeneity. Next, the ability of the novel scores to dis-
tinguish disease heterogeneity was assessed. Compared to LV-GCA, TA patients had higher stenotic (median 20, 
IQR 12–29 Vs 7, IQR 1–11, p < 0.001) and composite scores (median 24, IQR 15–33 Vs 13, IQR 9–22, p < 0.001), but 
lower dilation scores (median 0, IQR 0–5 Vs 6, IQR 0–11, p = 0.013, Supplementary Table 1 and Fig. 4). Moreover, 
the scores reflected important features of disease phenotype. For example, 67 patients (51%) had a dilation score of 
0, while four patients scored 0 for both stenotic and dilation scores. A qualitative assessment of the images derived 
from large arteries up to the carotid bifurcation confirmed that a dilation score of 0 accurately identified the patients 
without evidence of arterial dilation. A stenotic and dilation score of 0 was seen in the early “pre-angiographic” 
Figure 1. Multi-planar navigation to score arterial stenosis and dilation. A model artery showing stenosis and 
dilatation with interposed normal segments. Percent stenosis and dilation, and the length of stenotic (LS) and 
dilated (LD) segments are assessed with multi-oblique navigation: the planes of maximum stenosis and dilation 
are identified, together with a plane with a normal lumen. A valid reference plane excludes significant branching 
between the index and the reference planes. Orthogonality to the arterial axis is guaranteed by multi-planar 
navigation. The central panels show the identification of the smallest and largest arterial diameters in the plane 
of maximum stenosis (dS and DS), of maximal dilation (dD and DD) and in the plane with a normal arterial 
lumen (dN and DN).
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Stenosis - Scoring Individual Arteries
Percent stenosis Points Length* Extra-points
<50% 1 <1 cm 0
50–70% 2 1–3 cm 1
≥70% 3 3–10 cm 2
Functional occlusion 4 ≥10 cm 3
Dilation - Scoring Individual Arteries
Percent dilation Points Length Extra-points
<50% 1 <1 cm 0
50–100% 2 1–3 cm 1
≥100% or needing 3 3-10 cm 2
Procedures ≥10 cm 3
Core set of arteries
Ascending aorta Left axillary artery
Aortic arch Left common carotid artery
Thoracic aorta Coeliac artery
Abdominal aorta Superior mesenteric artery
Brachiocephalic artery Right renal artery
Right subclavian artery Left renal artery
Right axillary artery Right common iliac artery
Right common carotid artery Left common iliac artery
Left subclavian artery
Arterial Stenosis Score (ASS):   ∑ individual stenosis scores
Arterial Dilation Score (ADS):  ∑ individual dilation scores
Arterial Composite Score :     ASS+ADS
Table 1. Proposed scoring algorithm. *Lesion length was graded using a four-point scale: 0 for focal lesions 
(length < 10 mm), 1 for lesions above 10 and up to 30 mm, 2 for above 30 and up to 100 mm and 3 for >100 mm.
Figure 2. Scoring arterial involvement. (A) A stenotic lesion in the descending aorta in a maximum intensity 
projection (MIP) image using multi-oblique reconstructions. Coloured dotted lines show slice thickness and red 
ovals represent the artery at the planes of reference and maximum stenosis. (B) Measure of the smallest arterial 
diameter in the plane of maximum stenosis. (C) Assessment of lesion length. (D) Measure of the smallest 
diameter in a plane with a normal-appearing arterial lumen. Stenosis score of the descending aorta is 1 (<50% 
stenosis) +2 (length 30–100 mm) = 3; dilation score is 0.
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phase of LVV, diagnosed on the basis of a systemic inflammatory response and positive 18F-fluorodeoxyglucose PET 
imaging. These data show that the stenotic, dilation and composite scores can distinguish early and late phases of 
LVV and provide qualitative and quantitative definition of the arterial phenotype.
Cross-sectional validation against damage indices. To further assess the novel scoring algorithm, 
we analysed the relationship between the three scores and concurrent disease activity and damage. As expected, 
baseline scores did not correlate with CRP, ESR or any disease activity indices, either in TA or LV-GCA (Fig. 5A). 
Conversely, stenotic and composite scores in the whole cohort correlated with the Takayasu damage score (TADS) 
(rho = 0.716 and 0.627, respectively, p < 0.001), while the dilation score did not (Fig. 5B). Similar correlations 
between stenotic and composite scores and the TADS were found when the TA and LV-GCA groups were ana-
lysed separately (TA: rho = 0.655 and 0.587, p < 0.001, LV-GCA: 0.348, p = 0.041 and 0.407, p = 0.015). The sten-
otic and composite scores also reflected PGA damage in the whole cohort and in the TA subset (in all cases 
p < 0.001, Fig. 5C). In the LV-GCA subset only 4 patients exhibited moderate PGA damage and none had severe 
disease: accordingly, the correlation was not analysed. Overall, these data provide cross-sectional validation of 
Figure 3. Longitudinal scoring of a left subclavian artery stenosis. The lesion presented is scored 12 and 48 
months from baseline. (A) At 12 months, the percent stenosis was 50–70% and length 10–30 mm. The stenosis 
score was 2 + 1 = 3. (B) At 48 months, the percent stenosis is <50%, lesion length remains unchanged, and the 
stenosis score was 1 + 1 = 2.
Figure 4. Differences between stenotic, dilation and composite score values in TA and LV-GCA. In comparison 
to LV-GCA, TA patients had higher stenosis (ASS) and composite scores (ACS) but lower dilation scores (ADS), 
(*p = 0.013, ***p < 0.001).
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the stenotic and composite scores against disease-related damage scores in the whole LVV cohort and in both the 
TA and LV-GCA subgroups.
Longitudinal validation against activity measures. Sixty-seven patients underwent an additional 129 
scans at our institute, and these were included in the longitudinal analysis (median interval 18 months, IQR 
12–29). For longitudinal validation, changes in the novel scores between consecutive scans were calculated and 
related to matching disease activity measures using a mixed-effect linear model. The delta (Δ) of the stenotic, 
dilation and composite scores was scored as zero in 60, 115 and 53 scans, respectively. Of note, increased Δ 
stenotic, dilation and composite scores between scans were observed in patients with active disease as defined 
by ITAS2010, ITAS-CRP, ITAS-ESR and PGA (p < 0.005 for all indices), but not by NIH criteria (Table 2). This 
may reflect the more diverse elements of ITAS and the need to show changes in >2 of the 4 NIH criteria. Baseline 
scores were not related to any change in the scores during follow-up, either in the whole cohort (Table 2) or in the 
TA and LV-GCA subsets (not shown). These data provided an initial longitudinal validation of the novel scores, 
revealing rising scores in patients with active disease.
Longitudinal validation against a reference radiological assessment. Further longitudinal val-
idation of the new arterial scores established their accuracy against a reference assessment of disease evolution 
Figure 5. Cross-sectional validation of arterial injury scores against damage indices. (A) The stenotic, dilation 
and composite scores (y-axes) do not reflect disease activity, as assessed by physician global assessment (PGA) 
activity (x–axes). (B) The stenotic and composite scores correlate with damage as assessed by the Takayasu 
Arteritis Damage Score (TADS) (x-axes). (C) Stenotic and composite scores reflect damage as assessed by PGA 
damage (x-axes). Significance was evaluated by mixed-effect linear models (***p < 0.001).
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over time. In the absence of an accepted ‘gold standard’, we used a descriptive radiological assessment of arterial 
disease commonly applied in clinical practice. Each arterial stenosis or dilation was graded as “improved”, “sta-
ble” or “progressed” by two independent operators. Data from individual arteries were combined to obtain four 
distinct outcomes reflecting the evolution of stenotic and dilated lesions and the overall disease. The outcomes 
were separately defined as “improved”, if ≥1 artery improved and none progressed; “stable” if all arteries were 
unchanged, “mixed” if ≥1 artery improved and ≥1 progressed; “worsened” if ≥1 artery progressed and none 
improved (Supplementary Figs 2–4).
Interestingly, this detailed and standardised assessment showed that “reverse remodelling” is not rare in LVV. 
Stenotic disease improved in 33/129 scans, remained stable in 61/129, had a mixed evolution in 8/129 scans and 
worsened in 27/129 (Table 3). Therefore, the presence of arterial lesions and particularly stenosis, does not neces-
sarily indicate irreversible damage. In contrast, arterial dilation never improved, remained stable in 111/129 and 
worsened in 17/129 scans. A single case showed mixed evolution of arterial dilation.
Using mixed-effect linear models, we determined whether longitudinal changes in the novel stenosis, dila-
tion and composite scores reflected the evolution of stenotic disease, dilation and overall disease identified as 
improved, stable, worsened or mixed in the qualitative analyses above. This analysis showed that changes in the 
three novel scores were closely related to disease outcomes (Supplementary Table 2 and Fig. 6A, p < 0.001 for all 
scores), demonstrating sensitive discrimination of improving, stable and worsening arterial disease.
Receiver-operating characteristic (ROC) analyses. In order to identify changes in the novel scores that 
were predictive of arterial progression, the descriptive radiological assessment described above was used to strat-
ify the follow-up imaging studies based on the presence of progression in at least one artery between consecutive 
scans (Table 3 and Supplementary Fig. 2). ROC analyses were then performed using the novel stenotic, dilation 
and composite scores, with the aim of distinguishing progressive and non-progressive disease (Fig. 6B).
Using a mixed-effect linear model, the area under the curve (AUC) of the change in the stenosis score was 
0.949 (95%-IC: 0.883–0.995, p < 0.001). A change ≥1 had an observed sensitivity of 80% and specificity of 95% 
for detecting progressive stenosis. The AUC of the delta dilation score was 0.988 (95%-IC: 0.972–0.998, p < 0.001) 
and a Δ ≥ 1 gave a sensitivity of 67% and specificity of 99% for progressive dilation. Finally, the AUC for the 
change in composite score was 0.996 (95%-IC: 0.990–0.999, p < 0.001), with Δ ≥ 1 associated with overall pro-
gression (sensitivity 77%, specificity 96%). These data suggest that changes in all three scores have excellent spec-
ificity and good sensitivity for identifying arterial progression.
Δ Stenosis score (ASS) Δ Dilation scores (ADS) Δ Composite score (ACS)
Difference from 
inactive pts p-value
Difference from 
inactive pts p- value
Difference from 
inactive pts p-value
NIH activity 1.15 ± 0.81 0.162 0.34 ± 0.48 0.487 1.19 ± 1.04 0.257
ITAS2010 1.46 ± 0.50 0.005 0.35 ± 0.31 0.257 1.56 ± 0.66 0.020
ITAS-CRP 2.67 ± 0.72 <0.001 0.96 ± 0.39 0.019 3.27 ± 0.94 <0.001
ITAS-ESR 2.52 ± 0.78 0.002 1.12 ± 0.41 0.008 3.09 ± 1.02 0.003
PGA activity p(ANOVA) = 0.004 p(ANOVA) = 0.003 p(ANOVA) = 0.002
Grumbling 0.47 ± 0.39 0.232 0.78 ± 0.23 0.001 1.26 ± 0.50 0.001
Active 2.48 ± 0.73 0.001 1.04 ± 0.46 0.003 2.84 ± 0.94 0.004
Regression slope p-value
ΔASS as a function of ASS(t-1)† −0.021 ± 0.018 0.276
ΔADS as a function of ADS(t-1)† 0.056 ± 0.035 0.112
ΔACS as a function of ACS(t-1)† −0.004 ± 0.018 0.830
Table 2. Mixed effect linear model of the changes in ASS, ADS and ACS. LEGEND: CRP: C-reactive protein, 
ESR: Erythrocyte sedimentation rate, ITAS: Indian Takayasu Activity Score, NIH: National Institute of Health, 
PGA: physician global assessment. †ASS(t−1), ADS(t−1), ACS(t−1): ASS, ADS and ACS at the time −1, i.e. at the 
previous scan.
Stenotic Disease Dilation Overall Disease
Improved 33 (26%) 0 (0%) 30 (23%)
Stable 61 (47%) 111 (86%) 51 (40%)
Mixed 8 (6%) 1 (1%) 12 (9%)
Worsened 27 (21%) 17 (13%) 36 (28%)
Disease progression 35 (27%) 18 (14%) 48 (37%)
Table 3. Reference evolution of stenotic disease, dilation and overall disease. Improved scan: ≥1 lesions 
improved, 0 progressed. Stable scan: 0 lesions improved or progressed. Mixed scan: ≥1 lesions improved, ≥1 
progressed. Worsened scan: 0 lesions improved, ≥1 progressed.
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Discussion
The development and validation of three new imaging-based scores is a first step towards a standardised, quali-
tative and quantitative definition of arterial involvement in LVV. The data presented demonstrate that the scores 
facilitate cross-sectional assessment of the pattern and extent of arterial injury and allow longitudinal monitoring 
of disease progression. In light of the importance put upon the development of validated scores for imaging 
Figure 6. Longitudinal validation of the arterial injury scores and ROC analysis. (A) The change (Δ) in 
stenotic, dilation and composite scores (y-axes) reflects the outcomes of stenosis, dilation and overall disease 
respectively (x-axes). Significance was evaluated using mixed-effect linear models (***p < 0.001). (B) ROC 
curves of the Δ stenotic, dilation and composite scores for the detection of progressive arterial involvement.
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assessment in LVV by EULAR and OMERACT17,19, we believe the new scores have significant potential, particu-
larly for clinical trials, where they offer specific, relevant and quantitative primary outcome measures.
Although non-invasive imaging is essential for the management of LVV, debate continues concerning the 
optimal imaging modality for each stage. Likewise, it remains unclear whether confining imaging analysis to the 
arterial lumen is sufficient or whether extending it to include assessment of arterial wall inflammation and thick-
ening is beneficial17,23. Although MRI studies of the arterial wall may reveal changes consistent with active arte-
ritis including wall thickening and enhancement, the precise relationship with subsequent arterial remodelling 
is still unclear24. Recent studies suggest that combined FDG-PET/CT and MRA assessments may help to identify 
vasculitic lesions most likely to progress25,26 and confirmatory prospective studies are required.
In light of these uncertainties, and given the fact that luminal data derived from MRA or CTA studies directly 
reflect hemodynamic disturbance and the risk of end-organ ischemia, the new scores have so far been derived 
using exclusively luminal/angiographic data. This decision was made to allow the scores to: (a) be widely-applicable 
worldwide for multi-national clinical trials (MRA is much faster and less expensive than vessel wall imaging); (b) 
have conceptual similarity with the validated methods NASCET and ECST, and c) reflect haemodynamic altera-
tions by scoring the degree of luminal stenosis or dilation. A similar approach has recently been followed by the 
American Heart Association to grade coronary artery dilation and aneurysms in Kawasaki disease27. Recognizing 
the potential importance of arterial wall data, an important additional strength of the proposed algorithm is its 
plasticity and capacity for future refinement. Thus, if luminal and wall analyses ultimately prove to be complemen-
tary, the current scoring algorithm can be adapted to incorporate arterial wall data for future studies.
In the current study, the three novel scores quantified arterial involvement and provided an immediate over-
view of both its severity and the pattern of arterial remodelling in the individual patient. Further, the analyses 
demonstrated that longitudinal change in each score specifically and sensitively identified improvement and dete-
rioration in stenosis, dilation and overall arterial disease. Additionally, the scores allowed definition of the pattern 
and extent of arterial disease in groups of subjects. This was demonstrated by their ability to reflect significant 
differences between the TA and LV-GCA groups. Thus, application of the scores would improve identification 
of homogeneous groups for research studies including clinical trials. The stenosis and dilatation scores provide 
insight on the phenotype of remodelling, while the combined score reflects the total arterial damage burden. 
However, by combining the stenosis and dilatation scores there is a risk of one score ‘dampening’ the changes seen 
in the other and the potential impact of this requires further analysis in future studies. Likewise, dilatation and 
stenotic scores may be affected by other pathologies including diabetes mellitus, hypertension and atherosclerosis 
and this confounder must be born in mind when generating individual patient scores.
Longitudinal analysis revealed the dynamic nature of LVV lesions and highlighted the potential for reversi-
bility. Consistent with previous reports28,29, improvement was almost uniquely observed in stenotic lesions. The 
ability to sensitively detect treatment-related changes in arterial stenosis is particularly important when consid-
ering application of the new scores in future clinical trials. Moreover, it suggests the scores represent more than 
just a damage index. However, established (≥6 months) changes in the scores might also be used to extend the 
TADS, which currently only records physical signs of arterial disease and hence under-estimates visceral artery 
involvement30.
Feasibility of use was an important objective in the development of the scores and we have established that 
they can be derived from CTA or MRA data. Imaging data acquisition requires a few minutes and is compatible 
with clinical schedules and technology available worldwide. The current data analysis time of 30–40 mins per 
scan is longer than a standard radiology assessment, suggesting the algorithm is best suited for clinical trials and 
research studies, rather than routine clinical assessments. However, the increasing availability of automated soft-
ware for imaging analysis will reduce the analysis time.
Although comparable data was obtained by CTA and MRA, these modalities cannot yet be considered equiv-
alent until inter-modality reproducibility is directly studied. Additional limitations include the use of a standard-
ised descriptive radiological method for the evaluation of arterial disease evolution for the longitudinal validation 
of the novel scores. Although this approach has never been formally validated, it is the method most commonly 
used in clinical practice. To allow wider use of the novel scores, a limited core-set of 17 arteries most frequently 
involved in LVV were studied. Conceptually, this compares to the evaluation of a core-set of joints in rheumatoid 
arthritis. However, we accept that vasculitis might have involved arteries not included in the present study. A 
similar approach was adopted for the development of a combined arteritis damage score (CARDS), which used 
angiographic data to retrospectively investigate the CT or MRA studies of 41 TA and 55 GCA patients31. The 
CARDS quantifies arterial damage, reflecting stenosis, occlusion and dilatation in a single score. As also shown 
by the stenotic and composite scores herein, the median CARDS was significantly higher in GCA than TA31. The 
longitudinal phase of our current study and the use of three scores has now revealed correlation with disease 
activity and demonstrated that the new scores mirror disease evolution, reflecting both progressive arterial injury 
and lesion improvement.
In conclusion, a widely-applicable imaging-based scoring system which defines arterial involvement in 
LVV has been generated. Initial validation in a LVV cohort demonstrates the feasibility of the algorithm for a 
cross-sectional and longitudinal assessment of arterial disease. The new scoring system allows a standardised 
assessment of core features and facilitates the identification of homogeneous LVV subsets. We believe this is an 
important step towards fulfilling EULAR and OMERACT recommendations. We propose that the novel scores 
offer specific, objective and feasible arterial outcome measures which are essential for future clinical trials.
Methods
The validated NASCET and ESCT methods for the assessment of carotid atherosclerosis were used as the basis for 
the development of the novel scores. They were specifically modified for LVV as follows:
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 (1) A core-set of 17 arteries was defined on the basis of: (a) frequent involvement in LVV10,22 and (b) suitability 
for analysis by routine contrast-enhanced MRA and CTA (Table 1).
 (2) Each artery in the core-set received a stenosis and dilation score on the basis of both percentage and length 
of stenoses and dilations respectively (Fig. 1). Multiple lesions within the same artery were scored together, 
taking the worst percent stenosis/dilation and the sum of the lengths of stenotic lesions or dilations 
respectively.
 (3) Percent stenosis was calculated using a directly measured reference as required by NASCET whenever 
possible. Otherwise, a disease-free reference was estimated using ECST. The reference diameter was de-
rived from a disease-free section of each artery (where specifically the arterial lumen did not appear to be 
affected by vasculitis), located either upstream or downstream to the plane of the most severe involvement 
and without significant branching between the two planes. Percent stenosis was graded using a five-
point scale: 0 (no stenosis), 1 (<50% stenosis), 2 (50–70% stenosis), 3 (>70% stenosis) and 4 (occlusion/
sub-occlusion).
 (4) Percent dilatation is calculated similarly to stenosis and then graded using a four-point scale, acknowl-
edging that complete occlusion compromises downstream blood flow and threatens organ function more 
than an aneurysm. The reference for a dilated ascending aorta was estimated using age- and body surface 
area-adjusted normograms. Of note, to our knowledge, racially-adjusted normograms are not yet available.
 (5) Lesion length was graded using a four-point scale: 0 for focal lesions (length <10 mm), 1 for lesions above 
10 and up to 30 mm, 2 for above 30 and up to 100 mm and 3 for >100 mm.
 (6) The sum of the stenosis or dilation scores of the 17 arteries represented the total Arteritis Stenosis Score 
and Arteritis Dilation Score. These were combined to generate the Arteritis Composite Score.
 (7) The scores were designed to exclude apparent improvement following vascular interventions. In the case 
of previous vascular intervention, the pre-interventional lesion length and percent stenosis or dilation 
were obtained. The score allocated was derived from the most severe arterial involvement in the pre- and 
post-interventional periods.
 (8) In the case of anatomical variants such as multiple renal arteries, the score assigned to the renal artery 
reflected the most severely affected. In the case of a common origin for two different arteries, (e.g., bovine 
branching of the brachiocephalic trunk or common origin of the coeliac and superior mesenteric arter-
ies), the common tract was scored as if it belonged only to the largest artery (the brachiocephalic trunk or 
coeliac). In the event of an absent artery due to separate origins of its branches, the algorithm was adapted 
as follows: (i) absent brachiocephalic trunk, score omitted as the branches are included in the core-set, (ii) 
absent coeliac artery with separate origin of its branches from the aorta: the most severely affected artery 
was defined as the hypothetical coeliac. Table 1 summarises the final scoring algorithm.
Study sample. The novel scoring system was applied to the LVV cohort followed at Hammersmith Hospital 
between 2010 and 2017. Supplementary Methods provide details of the enrolment criteria, the definitions used 
for TA and LV-GCA, imaging protocols and the multi-parametric clinical characterisation. Imaging was repeated 
whenever clinically indicated, using the same imaging modality (i.e. CTA or MRA) as the baseline study. To avoid 
circularity, imaging data made available for clinical characterisation did not include the novel score values. This 
research was approved by Imperial College Healthcare and performed in accordance with the Declaration of 
Helsinki. Informed written consent was obtained from all participants.
Cross-sectional and longitudinal validation of the scoring system. Initial cross-sectional validation 
of the novel scores was performed using clinical measures of LVV damage (Takayasu Arteritis Damage Score 
(TADS) and Physician Global Assessment, (PGA) of damage). Longitudinal changes could not be validated with 
TADS or PGA damage, as they are insufficiently sensitive for assessing damage accrual. Therefore, longitudinal 
changes in the scores were validated against disease activity measures (NIH11, ITAS2010, ITAS-CRP, ITAS-ESR13, 
PGA activity and a 0–100 visual-analogue scale (VAS)), and against a typical radiological reference assessment 
of the evolution of stenosis, dilation and overall disease during follow-up. These three reference radiological 
assessments define disease evolution in four categories “improved”, “stable”, “mixed” and “worsened”, and the 
methodology is summarized in Fig. 2.
Two assessors compared each individual stenosis and dilation between consecutive scans, labelling lesions 
as “improved”, “stable” or “progressed”. Data were then combined to determine the global outcome of stenotic 
disease and dilation, respectively. Global outcome was labelled as “improved”, if ≥1 artery improved and none 
progressed; “stable” if all arteries were unchanged, “mixed” if ≥1 artery improved and ≥1 progressed; “worsened” 
if ≥1 artery progressed and none improved. The “mixed” category accounts for simultaneous improvement and 
worsening of lesions within the same patient. The outcome of overall disease was defined by including both 
stenoses and dilations. To ensure independence between the two different evaluations, longitudinal assessment 
of the stenosis, dilation and composite scores and the derivation of the three reference assessments were per-
formed at different times. A receiver-operating characteristic (ROC) analysis was subsequently performed to 
assess the accuracy of measured changes in the stenotic, dilation and composite scores for the evaluation of 
disease progression.
Statistical analysis. Non-parametric analysis was performed: quantitative variables are presented as median 
and inter-quartile ranges (IQR). Mann-Whitney and Kruskal-Wallis tests were used to compare scalar variables 
at baseline. Spearman rank correlation coefficients were calculated for the correlation analyses. Relationships 
between categorical variables were investigated by the χ2 test or the Fisher’s Exact Test, as appropriate. Intra- and 
inter-observer reliability were calculated using the intra-class correlation coefficient32 based on a 2-way random 
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effect model in a subset of 18 and 23 scans, randomly selected from our cohort. Previously established categories 
for expressing levels of reliability were used32. For longitudinal analysis of the changes in the scores, a mixed-effect 
linear model analysis was performed, to account for variable numbers of scans between patients. Similarly, the 
area under the ROC curve was calculated using a confidence interval of 95% (95%-IC) using a mixed effect linear 
model. A two-tailed p-value ≤0.05 was considered statistically significant. Statistical analysis was performed with 
IBM® SPSS® statistic, version 20 and R statistics.
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